Company Description
Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy.
The company offers Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure.
Its Aquadex FlexFlow system includes a console, disposable blood circuit set, and disposable catheter.
The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors in Austria, Belarus, Brazil, Colombia, the Czech Republic, Germany, Greece, Hong Kong, India, Indonesia, Israel, Italy, Panama, Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom.
The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021.
Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.
| Country | United States |
| Founded | 1999 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 38 |
| CEO | John Erb |
Contact Details
Address: 12988 Valley View Road Eden Prairie, Minnesota 55344 United States | |
| Phone | 952 345 4200 |
| Website | nuwellis.com |
Stock Details
| Ticker Symbol | NUWE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001506492 |
| CUSIP Number | 12542Q706 |
| ISIN Number | US67113Y4052 |
| Employer ID | 68-0533453 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| John L. Erb | Interim President, Interim Chief Executive Officer and Chairman of the Board |
| Robert B. Scott | Chief Financial Officer |
| Neil P. Ayotte Esq. | Senior Vice President, General Counsel, Secretary and Chief Compliance Officer |
| Betsy Riemenschneider | Vice President of Sales |
| Sandra Eayrs | Chief Human Resources Officer |
| Dr. John Lynn Jefferies FACC, M.B.A., M.D., M.P.H. | Chief Medical Officer and Member of Medical Advisory Board |
| Paul Wotta | Corporate Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 14, 2025 | ARS | Filing |
| Apr 14, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 3, 2025 | 8-K | Current Report |
| Apr 1, 2025 | PRE 14A | Other preliminary proxy statements |
| Mar 18, 2025 | SCHEDULE 13G/A | Filing |
| Mar 11, 2025 | 10-K | Annual Report |
| Mar 11, 2025 | 8-K | Current Report |
| Feb 24, 2025 | 8-K | Current Report |
| Dec 20, 2024 | EFFECT | Notice of Effectiveness |
| Dec 20, 2024 | 424B3 | Prospectus |